Abstract:Inexpensive blood tests have been well established as alternatives to liver biopsies to evaluate liver fibrosis in CHB patients. Here, we aim to compare their diagnostic accuracy in assessing liver fibrosis and necroinflammation. A retrospective study was performed to evaluate the predictive value of non-invasive models in chronic hepatitis B patients with liver fibrosis by the area under receiver operating characteristic curve (AUROC). The clinical data of 160 patients were collected from medical records. Of the 160 consecutive treatment-naïve CHB patients, 29 (16%) had significant fibrosis and 34 (21%) had severe necroinflammation. The AUROC of the gamma-glutamyl transpeptidase to platelet ratio (GPR) (0.761, 95% CI 0.671–0.850) for predicting significant fibrosis was significantly higher than that of the aspartate transaminase-to-platelet ratio index (APRI) (0.680, 95% CI 0.585–0.774, p = 0.034), but comparable with the fibrosis index based on four factors (Fib-4) (0.746, 95% CI 0.656–0.836, p = 0.703), while for predicting severe necroinflammation, the performance of the GPR (AUROC = 0.869, 95% CI 0.800–0.937) was better than the APRI (AUROC = 0.816, 95% CI 0.740–0.892, p = 0.085) and Fib-4 (0.792, 95% CI 0.711–0.873, p = 0.023). GPR is a satisfactory model to stage liver fibrosis and to grade necroinflammation activity, representing a convenient non-invasive alternative to liver biopsy in China. los análisis de sangre asequibles se han consolidado como alternativas a la biopsia hepática para evaluar la fibrosis hepática en pacientes con HBC. En este caso, nuestro objetivo es comparar su precisión diagnóstica en la evaluación de la fibrosis hepática y en la necroinflamación. se realizó un estudio retrospectivo para evaluar el valor pronóstico de los modelos no invasivos en pacientes con hepatitis B crónica con fibrosis hepática en el área bajo la curva de rendimiento diagnóstico (AUROC). Se recopilaron los datos clínicos de 160 pacientes a partir de las historias clínicas. De 160 pacientes HBC que no habían recibido tratamiento consecutivo, 29 (16%) presentaron una importante fibrosis y 34 (21%), necroinflamación grave. La AUROC de la gammaglutamiltranspeptidasa respecto a la proporción de plaquetas (GPR) (0,761; IC95%: 0,671-0,850) para pronosticar una fibrosis importante fue considerablemente más alta que el índice de relación aspartato-transaminasa-plaquetas (APRI) (0,680; IC95%: 0,585-0,774; p = 0,034), pero comparable con el índice de fibrosis basado en cuatro factores (Fib-4) (0,746; IC95%: 0,656-0,836; p = 0,703), mientras que para el pronóstico de la necroinflamación grave, el rendimiento de GPR (AUROC = 0,869; IC95%: 0,800-0,937) fue mejor que el de APRI (AUROC = 0,816; IC95%: 0,740-0,892; p = 0,085) y el de Fib-4 (0,792; IC95%: 0,711-0,873; p = 0,023). el GPR es un modelo satisfactorio para clasificar la fibrosis hepática y para calificar la actividad de la necroinflamación, y representa una alternativa práctica y no invasiva a la biopsia hepática en China.

Comparison of Non-Invasive Models for Predicting Liver Damage in Chronic Hepatitis B Patients

The Diagnostic Value of the Fib-4 Index for Staging Hepatitis B-Related Fibrosis: A Meta-Analysis

Predictive Value of the Red Blood Cell Distribution Width-to-platelet Ratio for Hepatic Fibrosis.

A Novel Noninvasive Algorithm For The Assessment Of Liver Fibrosis In Patients With Chronic Hepatitis B Virus Infection

A novel predictive model using routinely clinical parameters to predict liver fibrosis in patients with chronic hepatitis B.

Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China

Evaluation and comparison of the diagnostic performance of routine blood tests in predicting liver fibrosis in chronic hepatitis B infection.

Evaluation of Noninvasive Diagnostic Models of Liver Fibrosis in Patients with Chronic Hepatitis B

Comparison of GPR, APRI and FIB-4 in predicting severity of liver fibrosis associated with HBeAg-negative chronic hepatitis B

A Novel Non-invasive Model Based on GPR for the Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B

Evaluation and Comparison of Thirty Non-invasive Models for Diagnosing Liver Fibrosis in Chinese Hepatitis B Patients.

The Prediction and Validation of Liver Fibrosis by a Noninvasive Model and Validation in Patients with Chronic Hepatitis B

Diagnostic Estimation of Noninvasive Tests for Hepatic Fibrosis in Chronic Hepatitis B Patients Without a Gold Standard

Establishment and Validation of a Simple Noninvasive Model to Predict Significant Liver Fibrosis in Patients with Chronic Hepatitis B

A Novel Non-Invasive Model for the Prediction of Advanced Liver Fibrosis in Chronic Hepatitis B Patients with NAFLD.

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

A Novel Noninvasive Index for the Prediction of Moderate to Severe Fibrosis in Chronic Hepatitis B Patients

Noninvasive Models to Assess Liver Inflammation and Fibrosis in Chronic HBV Infected Patients with Normal or Mildly Elevated Alanine Transaminase Levels: Which One Is Most Suitable?

Staging of Liver Fibrosis in Chronic Hepatitis B Patients with A Composite Predictive Model: A Comparative Study

Development and Validation of a Non-Invasive Model for Predicting Liver Cirrhosis in Patients with Chronic Hepatitis B

Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B.